Research on required specifications of tele-monitoring system for oncology patients receiving ambulatory chemotherapy treatments

Research on required specifications of tele-monitoring system for oncology patients receiving ambulatory chemotherapy treatments - Research on required specifications of tele-monitoring system for oncology patients receiving ambulatory chemotherapy treatments

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000037808

Enrollment

Registered

2019-11-01

Start date

2019-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer, colorectal cancer, breast cancer

Interventions

Patients register their vital information and interview items every day on a patient lending terminal for tele-monitoring.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with gastric cancer, colorectal cancer, or breast cancer 2. Patients recieving chemotherapy using the following drugs at an outpatient clinic i S-1 ii capecitabin iii regorafenib iv TAS-102 v tegafur-uracil 3. Patients who can operate iPad or iPhone by themselves

Exclusion criteria

Exclusion criteria: 1. Patients who cannot operate iPad or iPhone by themselves 2. Patients who have confirmed adverse events with the above drugs

Design outcomes

Primary

Measure	Time frame
Availability of tele-monitoring system	—

Secondary

Measure	Time frame
Results obtained during the tele-monitoring system usage period	—

Countries

Japan

Contacts

Public ContactAkitaka Sugishita

Nagoya University Hospital Center for Advanced Medicine and Clinical Research

asugishita@med.nagoya-u.ac.jp+81-52-744-2942

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026